Ratios Glaxo Smith Kline

56
Description Dec 31, 2010 Net sales 18,916,191 Cost of sales -14,063,242 Gross profit 4,852,949 Selling, marketing and distribution expenses -2,301,516 Administrative expenses -826,236 Other operating expenses -171,143 Other operating income 397,696 Operating Profit 1,951,750 Financial charges -20,026 Profit before taxation 1,931,724 Taxation -874,341 Profit after taxation for the year 1,057,383 Other comprehensive income Fair value gain on available-for-sale investments 3,544 Reversal of deficit on revaluation of available-for-sale investments 0 Deferred tax thereon -1,240 2,304 Total comprehensive income 1,059,687 Earnings per share 4.42 Stock Price Per Share 88.4 Total outstanding shares 31,771,778 Net Sales Per Share 0.60 Income Statement Glaxo Smith Kline (GSK) As of 31st December 2010, 2011, 2012 Rs in (000)

Transcript of Ratios Glaxo Smith Kline

Page 1: Ratios Glaxo Smith Kline

Description Dec 31, 2010

Net sales 18,916,191

Cost of sales -14,063,242

Gross profit 4,852,949

Selling, marketing and distribution expenses -2,301,516

Administrative expenses -826,236

Other operating expenses -171,143

Other operating income 397,696

Operating Profit 1,951,750

Financial charges -20,026

Profit before taxation 1,931,724

Taxation -874,341

Profit after taxation for the year 1,057,383

Other comprehensive income

Fair value gain on available-for-sale investments 3,544

Reversal of deficit on revaluation of available-for-sale investments 0

Deferred tax thereon -1,240

2,304Total comprehensive income 1,059,687

Earnings per share 4.42

Stock Price Per Share 88.4

Total outstanding shares 31,771,778

Net Sales Per Share 0.60

Income Statement

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs in (000)

Page 2: Ratios Glaxo Smith Kline

Dec 31, 2011 Dec 31, 2012

21,750,147 23,149,964

-15,931,728 -17,068,949

5,818,419 6,081,015

-2,790,373 -3,046,675

-1,022,493 -771,322

-194,066 -192,617

461,927 289,207

2,273,414 2,359,608

-36,526 -47,512

2,236,888 2,312,096

-1,095,972 -992,000

1,140,916 1,320,096

0 0

128 0

-45 0

83 0

1,140,999 1,320,096

4.77 5.02

73.93 73.31

239,269,179 263,196,097

0.09 0.09

Income Statement

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs in (000)

Page 3: Ratios Glaxo Smith Kline

Description Dec 31, 2010

EQUITY AND LIABILITIES

CURRENT LIABILITIES

Trade and other payables 3,429,292

Provisions 131,001

TOTAL CURRENT LIABILITIES 3,560,293

NON-CURRENT LIABILITIES

Staff retirement benefits 115,240

Deferred taxation 416,452

TOTAL NON-CURRENT LIABILITIES 531,692

TOTAL LIABILITIES 4,091,985

SHARE CAPITAL AND RESERVES

Share capital 1,964,118

Reserves 8,835,696

Shareholder's Equity 10,799,814

TOTAL EQUITY AND LIABILITIES 14,891,799

ASSETS

NON-CURRENT ASSETS

Fixed assets

Property, plant and equipment 4,189,996

Intangible - Goodwill 955,742

Long-term loans to employees 73,590

Long-term deposits 11,871

Total Non-current Assets 5,231,199

CURRENT ASSETS

Stores and spares 150,632

Stock-in-trade 4,312,535

Trade debts 295,762

Loans and advances 144,267

Trade deposits and prepayments 96,234

Interest accrued 19,443

Refunds due from government 17,534

Other receivables 290,056

Taxation - payments less provision 623,410

Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)

Page 4: Ratios Glaxo Smith Kline

Investments 901,955

Cash and bank balances 2,808,772

Total Current Assets 9,660,600

TOTAL ASSETS 14,891,799

Page 5: Ratios Glaxo Smith Kline

Dec 31, 2011 Dec 31, 2012

3,663,772 3,950,339

217,239 200,716

3,881,011 4,151,055

19,706 50,381

428,296 570,298

448,002 620,679

4,329,013 4,771,734

2,392,691 2,631,960

8,715,881 8,839,631

11,108,572 11,471,591

15,437,585 16,243,325

4,771,175 5,784,694

955,742 955,742

82,005 81,959

11,780 16,761

5,820,702 6,839,156

159,268 170,501

5,602,526 5,080,220

343,404 350,362

163,378 243,070

54,657 92,542

30,372 12,205

17,104 40,759

319,800 438,674

600,742 660,092

Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)

Page 6: Ratios Glaxo Smith Kline

196,706 198,118

2,128,926 2,117,626

9,616,883 9,404,169

15,437,585 16,243,325

Page 7: Ratios Glaxo Smith Kline

Description Dec 31, 2010

Net sales 100.00%

Cost of sales -74.34%

Gross profit 25.66%

Selling, marketing and distribution expenses -12.17%

Administrative expenses -4.37%

Other operating expenses -0.90%

Other operating income 2.10%

Operating Profit 10.32%

Financial charges -0.11%

Profit before taxation 10.21%

Taxation -4.62%

Profit after taxation for the year 5.59%

Other comprehensive income

Fair value gain on available-for-sale investments 0.02%

Reversal of deficit on revaluation of available-for-sale investments 0%

Deferred tax thereon -0.01%

Total comprehensive income 5.60%

Earnings per share 0.00%

Vertical Analysis Of Income Statement

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)

Page 8: Ratios Glaxo Smith Kline

Dec 31, 2011 Dec 31, 2012

100.00% 100.00%

-73.25% -73.73%

26.75% 26.27%

-12.83% -13.16%

-4.70% -3.33%

-0.89% -0.83%

2.12% 1.25%

10.45% 10.19%

-0.17% -0.21%

10.28% 9.99%

-5.04% -4.29%

5.25% 5.70%

0.00% 0.00%

0.00% 0.00%

0.00% 0.00%

5.25% 5.70%

0.00% 0.00%

Vertical Analysis Of Income Statement

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)

Page 9: Ratios Glaxo Smith Kline

Description Dec 31, 2010

EQUITY AND LIABILITIES

CURRENT LIABILITIES

Trade and other payables 23.03%

Provisions 0.88%

TOTAL CURRENT LIABILITIES 23.91%

NON-CURRENT LIABILITIES

Staff retirement benefits 0.77%

Deferred taxation 2.80%

TOTAL NON-CURRENT LIABILITIES 3.57%

TOTAL LIABILITIES 27.48%

SHARE CAPITAL AND RESERVES

Share capital 13.19%

Reserves 59.33%

Shareholder's Equity 72.52%

TOTAL EQUITY AND LIABILITIES 100.00%

ASSETS

NON-CURRENT ASSETS

Fixed assets

Property, plant and equipment 28.14%

Intangible - Goodwill 6.42%

Long-term loans to employees 0.49%

Long-term deposits 0.08%

Total Non-current Assets 35.13%

CURRENT ASSETS

Stores and spares 1.01%

Stock-in-trade 28.96%

Trade debts 1.99%

Loans and advances 0.97%

Trade deposits and prepayments 0.65%

Interest accrued 0.13%

Refunds due from government 0.12%

Other receivables 1.95%

Taxation - payments less provision 4.19%

Vertical Analysis of Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in Rupees

Page 10: Ratios Glaxo Smith Kline

Investments 6.06%

Cash and bank balances 18.86%

Total Current Assets 64.87%

TOTAL ASSETS 100.00%

Page 11: Ratios Glaxo Smith Kline

Dec 31, 2011 Dec 31, 2012

23.73% 24.32%

1.41% 1.24%

25.14% 25.56%

0.13% 0.31%

2.77% 3.51%

2.90% 3.82%

28.04% 29.38%

15.50% 16.20%

56.46% 54.42%

71.96% 70.62%

100.00% 100.00%

30.91% 35.61%

6.19% 5.88%

0.53% 0.50%

0.08% 0.10%

37.70% 42.10%

1.03% 1.05%

36.29% 31.28%

2.22% 2.16%

1.06% 1.50%

0.35% 0.57%

0.20% 0.08%

0.11% 0.25%

2.07% 2.70%

3.89% 4.06%

Vertical Analysis of Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in Rupees

Page 12: Ratios Glaxo Smith Kline

1.27% 1.22%

13.79% 13.04%

62.30% 57.90%

100.00% 100.00%

Page 13: Ratios Glaxo Smith Kline

Description Dec 31, 2010 Dec 31, 2011

Net sales 100.0% 114.98%

Cost of sales 100.0% 113.29%

Gross profit 100.0% 119.89%

Selling, marketing and distribution expenses 100.0% 121.24%

Administrative expenses 100.0% 123.75%

Other operating expenses 100.0% 113.39%

Other operating income 100.0% 116.15%

Operating Profit 100.0% 116.48%

Financial charges 100.0% 182.39%

Profit before taxation 100.0% 115.80%

Taxation 100.0% 125.35%

Profit after taxation for the year 100.0% 107.90%

Other comprehensive income

Fair value gain on available-for-sale investments 100.0% 0.00%Reversal of deficit on revaluation of available-for-

sale investments 0.0% 0.00%

Deferred tax thereon 100.0% 3.63%

100.0% 3.60%Total comprehensive income 100.0% 107.67%

Earnings per share 100% 107.92%

Horizontal Analysis Of Income Statement

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)

Page 14: Ratios Glaxo Smith Kline

Dec 31, 2012

122.38%

121.37%

125.31%

132.38%

93.35%

112.55%

72.72%

120.90%

237.25%

358.15%

119.69%

124.85%

0.00%

0.00%

0.00%

0.00%

124.57%

113.57%

Horizontal Analysis Of Income Statement

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)

Page 15: Ratios Glaxo Smith Kline

Description Dec 31, 2010

EQUITY AND LIABILITIES

CURRENT LIABILITIES

Trade and other payables 100.00%

Provisions 100.00%

TOTAL CURRENT LIABILITIES 100.00%

NON-CURRENT LIABILITIES

Staff retirement benefits 100.00%

Deferred taxation 100.00%

TOTAL NON-CURRENT LIABILITIES 100.00%

TOTAL LIABILITIES 100.00%

SHARE CAPITAL AND RESERVES

Share capital 100.00%

Reserves 100.00%

Shareholder's Equity 100.00%

TOTAL EQUITY AND LIABILITIES 100.00%

ASSETS

NON-CURRENT ASSETS

Fixed assets

Property, plant and equipment 100.00%

Intangible - Goodwill 100.00%

Long-term loans to employees 100.00%

Long-term deposits 100.00%

Total Non-current Assets 100.00%

CURRENT ASSETS

Stores and spares 100.00%

Stock-in-trade 100.00%

Trade debts 100.00%

Loans and advances 100.00%

Trade deposits and prepayments 100.00%

Interest accrued 100.00%

Refunds due from government 100.00%

Other receivables 100.00%

Taxation - payments less provision 100.00%

Horizontal Analysis Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in Rupees

Page 16: Ratios Glaxo Smith Kline

Investments 100.00%

Cash and bank balances 100.00%

Total Current Assets 100.00%

TOTAL ASSETS 100.00%

Page 17: Ratios Glaxo Smith Kline

Dec 31, 2011 Dec 31, 2012

106.84% 115.19%

165.83% 153.22%

109.01% 116.59%

17.10% 43.72%

102.84% 136.94%

84.26% 116.74%

105.79% 116.61%

121.82% 134.00%

98.64% 100.04%

102.86% 106.22%

103.67% 109.08%

113.87% 138.06%

100.00% 100.00%

111.43% 111.37%

99.23% 141.19%

111.27% 130.74%

105.73% 113.19%

129.91% 117.80%

116.11% 118.46%

113.25% 168.49%

56.80% 96.16%

156.21% 62.77%

97.55% 232.46%

110.25% 151.24%

110.25% 105.88%

Horizontal Analysis Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in Rupees

Page 18: Ratios Glaxo Smith Kline

21.81% 21.97%

75.80% 75.39%

99.55% 97.35%

103.67% 109.08%

Page 19: Ratios Glaxo Smith Kline

2010

Definition:

Current Assets 2.71 =

Current Liabilities

Total quick assets 1.50 =

Current Liabilities

Current Liabilities 0.83 =

Inventory

Total cash assets 0.79 =

Current Liabilities

365 Days 115.84 =

Inventory Turnover Ratio

365 Days 5.60 =

Recivable Turnover Ratio

365 Days 5.71 =

Payable Turnover Raito

115.73

Liquidity Measurement Ratios

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012

1 Current Ratio =

2 Quick Ratio =

3Current Liabilities to

Inventory Ratio=

4 Cash Ratio =

5Average Inventory

Processing Period (AIPP)=

6Average Recivable

Collection Period (ARCP)=

AIPP + ARCP - APPP

7Averagepayable Payment

Period (APPP)=

8 Cash Conversion Cycle =

2.71

2.48

3.00

Page 20: Ratios Glaxo Smith Kline

2.48

1.50

1.03

0.83

0.69 0.79

0.55

0.00

0.50

1.00

1.50

2.00

2.50

2010 2011

115.84 113.58

5.60 5.37 5.71 5.76

115.73 113.18

0.00

20.00

40.00

60.00

80.00

100.00

120.00

140.00

2010 2011

Page 21: Ratios Glaxo Smith Kline

2011 2012

9,660,600.00 2.48 = 9,616,883.00 2.27 = 9,404,169.00

3,560,293.00 3,881,011.00 4,151,055.00

5,348,065.00 1.03 = 4,014,357.00 1.04 = 4,323,949.00

3,560,293.00 3,881,011.00 4,151,055.00

3,560,293.00 0.69 = 3,881,011.00 0.82 = 4,151,055.00

4,312,535.00 5,602,526.00 5,080,220.00

2,808,772.00 0.55 = 2,128,926.00 0.51 = 2,117,626.00

3,560,293.00 3,881,011.00 4,151,055.00

365 113.58 = 365 114.22 = 3653.15 3.21 3.20

365 5.37 = 365 6.92 = 365

65.22 68.01 52.77

365 5.76 = 365 5.52 = 365

63.95747594 63.33690638 66.07441446

Days 113.18 Days 115.61 Days

Liquidity Measurement Ratios

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012

Current Ratio

Page 22: Ratios Glaxo Smith Kline

2.27

1.04

0.82

0.51

2012

Current Ratio

Quick Ratio

Current Liabilities toInventory Ratio

Cash Ratio

114.22

6.92 5.52

115.61

2012

Average Inventory Processing Period (AIPP)

Average Recivable Collection Period (ARCP)

Averagepayable Payment Period (APPP)

Cash Conversion Cycle

Page 23: Ratios Glaxo Smith Kline

2010

Net Income 7.10% =

Total Assets

Net Income 9.79% =

Owners' Equity

Gross Profit 25.66% =

Net Sales

Operating Profit 10.32% =

Net Sales

Net Income 5.59% =

Net Sales

Earnings Before Interest and Taxes 13.11% =

Total Assets

Profitability Indicator Ratios

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in Rupees

Definition:

1Return on Assets Ratio =

2Return on Equity Ratio =

3=

6=

Gross Profit Margin

Ratio

Operating Profit Margin

Ratio

Net Profit Margin Ratio

Basic Earnings Power

Ratio

4=

5=

25.66% 26.75%

20.00%

25.00%

30.00%

Page 24: Ratios Glaxo Smith Kline

7.10% 7.39%

9.79% 10.27% 10.32% 10.45%

5.59% 5.25%

13.11%

14.73%

0.00%

5.00%

10.00%

15.00%

2010 2011

Page 25: Ratios Glaxo Smith Kline
Page 26: Ratios Glaxo Smith Kline

2011 2012

1,057,383.00 7.39% = 1,140,916.00 8.13% = 1,320,096.00

14,891,799.00 15,437,585.00 16,243,325.00

1,057,383.00 10.27% = 1,140,916.00 11.51% = 1,320,096.00

10,799,814.00 11,108,572.00 11,471,591.00

4,852,949.00 26.75% = 5,818,419.00 26.27% = 6,081,015.00

18,916,191.00 21,750,147.00 23,149,964.00

1,951,750.00 10.45% = 2,273,414.00 10.19% = 2,359,608.00

18,916,191.00 21,750,147.00 23,149,964.00

1,057,383.00 5.25% = 1,140,916.00 5.70% = 1,320,096.00

18,916,191.00 21,750,147.00 23,149,964.00

1,951,750.00 14.73% = 2,273,414.00 14.53% = 2,359,608.00

14,891,799.00 15,437,585.00 16,243,325.00

Profitability Indicator Ratios

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in Rupees

26.27% Return on Assets Ratio

Return on Equity Ratio

Gross Profit Margin Ratio

Page 27: Ratios Glaxo Smith Kline

8.13%

11.51% 10.19%

5.70%

14.73% 14.53%

2012

Gross Profit Margin Ratio

Operating Profit MarginRatio

Net Profit Margin Ratio

Basic Earnings Power Ratio

Page 28: Ratios Glaxo Smith Kline
Page 29: Ratios Glaxo Smith Kline
Page 30: Ratios Glaxo Smith Kline
Page 31: Ratios Glaxo Smith Kline
Page 32: Ratios Glaxo Smith Kline
Page 33: Ratios Glaxo Smith Kline
Page 34: Ratios Glaxo Smith Kline

Definition:

Total Liabilities 27.48% =

Total Assets

Earnings Before Interest and Taxes 97.46% =

Interest Expense

Long-Term Debs 0.11% =

Long-Term Debs + Owners' Equity

Total Debts 0.05 =

Owners' Equity4 Debt/Equity Ratio =

3 Capitalization Ratio =

2Interest Coverage Ratio

=

Debt Ratios

ABBOT

For

2010, 2011, 2012,

1 Total Debt Ratio =

27.48% 28.04%

97.46%

62.24%

0.11% 0.11%0.05

0.00%

20.00%

40.00%

60.00%

80.00%

100.00%

120.00%

Page 35: Ratios Glaxo Smith Kline

0.11% 0.11%0.00%

2010 2011

Page 36: Ratios Glaxo Smith Kline

2010 2011

28.04% = 29.38% =

62.24% = 49.66% =

0.11% = 0.15% =

11,871.00 + 10,799,814.00 11,780.00 + 11,108,572.00

0.04 = 0.05 =

10,799,814.00 11,108,572.00

531,692.00 448,002.00

2,002,600.00 3,652,600.00

11,871.00 11,780.00

1,951,750.00 2,273,414.00

Debt Ratios

ABBOT

For

2010, 2011, 2012,

4,091,985.00 4,329,013.00

14,891,799.00 15,437,585.00

29.38%

49.66%

0.11% 0.15% 0.04 0.05

Total Debt Ratio

Interest CoverageRatioCapitalization Ratio

Debt/Equity Ratio

Page 37: Ratios Glaxo Smith Kline

0.11% 0.15%

2011 2012

Page 38: Ratios Glaxo Smith Kline

2012

16,761.00 + 11,471,591.00

11,471,591.00

620,679.00

2,359,608.00

4,751,200.00

16,761.00

Debt Ratios

ABBOT

For

2010, 2011, 2012,

4,771,734.00

16,243,325.00

Total Debt Ratio

Interest CoverageRatioCapitalization Ratio

Debt/Equity Ratio

Page 39: Ratios Glaxo Smith Kline
Page 40: Ratios Glaxo Smith Kline

Definition: 2010

Cost of Good Sold 3.15 =

Average Inventory

Total Sales 65.22 =

Account Recivale

Total Sales 63.96 =

Trade Debt

Total Sales 4.51 =

Property Plant and Equipment

= Total Sales 1.27 =

Total Assets

= Total Assets 1.30 =

Owners' Equity

=

4Fixed Assets Turnover

Ratio=

5

Operating Performance Ratios

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012

1 Inventory Turnover Ratio =

2Recivables Turnover

Ratio=

Total Assets Ratio

6 Asset to Equity Ratio

3 Debtors Turnover Ratio

3.15 3.21

65.22 68.01

63.96 63.34

4.51 4.56 1.27 1.41 1.30 1.43

10.00

20.00

30.00

40.00

50.00

60.00

70.00

80.00

Page 41: Ratios Glaxo Smith Kline

3.15 3.21 4.51 4.56 1.27 1.41 1.30 1.43

0.00

10.00

2010 2011

Page 42: Ratios Glaxo Smith Kline

2011 2012

14,063,242.00 3.21 = 15,931,728.00 3.20 = 17,068,949.00

4,463,167.00 4,957,530.50 5,341,373.00

18,916,191.00 68.01 = 21,750,147.00 52.77 = 23,149,964.00

290,056.00 319,800.00 438,674.00

18,916,191.00 63.34 = 21,750,147.00 66.07 = 23,149,964.00

295,762.00 343,404.00 350,362.00

$18,916,191 4.56 = $21,750,147 4.00 = $23,149,964

$4,189,996 $4,771,175 $5,784,694

18,916,191.00 1.41 = 21,750,147.00 1.43 = 23,149,964.00

14,891,799.00 15,437,585.00 16,243,325.00

14,063,242.00 1.43 = 15,931,728.00 1.49 = 17,068,949.00

10,799,814.00 11,108,572.00 11,471,591.00

Operating Performance Ratios

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012

3.20

52.77

66.07

4.00 1.43 1.43 1.49

Inventory Turnover Ratio

Recivables Turnover Ratio

Debtors Turnover Ratio

Fixed Assets Turnover Ratio

Total Assets Ratio

Asset to Equity Ratio

Page 43: Ratios Glaxo Smith Kline

3.20 4.00 1.43 1.43 1.49

2012

Page 44: Ratios Glaxo Smith Kline
Page 45: Ratios Glaxo Smith Kline

Profitability Ratios 2010

Definition:

Stock Price Per Share 148.51 =

Net Sales per Share

Annual Dividend per Share 0.05 =

Stock Price per Share

Stock Price Per Share 0.00 =

Total Assets-Intangible Assets-Liabilities

Stock Price per Share 20.00 =

Earnings per Share

Investment Valuation Ratios

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012, 2013

1 Price/Sales Ratio =

2 Dividend Yield =

3 Price/Book Value Ratio =

4 Price/Earnings Ratio =

2.287752675 2.696322657 2.287752675

0.025156007 0.071223931 0.074257733

7.315589354 9.20242915

39.75193628

14.04022471

0

5

10

15

20

25

30

35

40

45

Page 46: Ratios Glaxo Smith Kline

0.025156007 0.071223931 0.0742577330

2010 2011

Page 47: Ratios Glaxo Smith Kline

2011 2012

$88.42 813.29 = $73.93 833.47 = $73.31

$0.60 $0.09 $0.09

$4.00 0.05 = $4.00 0.05 = $4.00

$88.42 $73.93 $73.31

$88.42 0.00 = $73.93 0.00 = $73.31

9,844,072 10,152,830 10,515,849

$88.42 15.50 = $73.93 14.60 = $73.31

$4.42 $4.77 $5.02

Investment Valuation Ratios

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012, 2013

2.287752675 2.696322657

0.074257733 0.078499682

7.315589354 9.20242915

13.46661096 12.73890518

Price/Sales Ratio

Dividend Yield

Price/Book Value Ratio

Price/Earnings Ratio

Page 48: Ratios Glaxo Smith Kline

0.074257733 0.078499682

2012 2013

Page 49: Ratios Glaxo Smith Kline
Page 50: Ratios Glaxo Smith Kline

S.No Ratios Name 2010 2011 2012 2013 Average

1 Current Ratios 1.72 1.45 1.25 1.08 1.38

2 Quick Ratio 1.19 1.40 0.80 0.74 1.03

3 Current Liabilities to Inventory Ratio 2.47 2.98 3.33 3.88 3.17

4 Cash Ratio 0.60 0.56 0.49 0.39 0.51

5 Average inventory processing period (AIPP) 50 56 50 50 52

6 Average receivable collection period (ARCP) 65 76 62 57 65

7 Average payables payment period (APPP) 14 26 28 33 25

8 Cash Conversion Cycle Days 101 107 84 74 91

1 Return on Assets Ratio 4.37% 11.80% 11.42% 14.11% 10%

2 Return on Equity Ratio 21.69% 50.53% 54.27% 72.19% 50%

3 Gross Profit Margin Ratio 73.26% 73.23% 70.13% 67.61% 71%

4 Operating Profit Margin Ratio 13.32% 28.51% 13.55% 27.61% 21%

5 Net Profit Margin Ratio 5.76% 19.21% 17.27% 20.51% 16%

6 Basic Earnings Power Ratio 10.49% 18.93% 18.61% 19.14% 17%

7 Earnings per Share Ratio 0.97$ 3.24$ 2.86$ 3.57$ 2.66

1 Total Debt Ratio 0.79 0.75 0.77 0.79 0.77

2 Interest Coverage Ratio 5.11 11.35 9.98 10.16 9.15

3 Capitalization Ratio 0.66 0.54 0.64 0.67 0.63

4 Debt/Equity Ratio 2.00 1.43 1.78 2.39 1.90

1 Inventory Turnover Ratio 7.37 6.48 7.28 7.30 7.11

2 Receivables turnover Ratio 5.60 4.80 5.91 6.37 5.67

3 Payables turnover Ratio 25.92 14.19 13.05 11.01 16.04

4 Fixed Assets Turnover Ratio 3.09 2.81 3.09 3.23 3.05

5 Total Assets Turnover Ratio 0.76 0.61 0.66 0.69 0.68

6 Asset to Equity Ratio 4.97 4.28 4.75 5.11 4.78

1 Price/Sales Ratio 2.29 2.70 2.29 2.70 2.49

2 Dividend Yield 2.52% 7.12% 7.43% 7.85% 6.23%

Operating Performance Ratios

Investment Valuation Ratios

SUMMARY OF RATIOS

Glaxo Smith Kline (GSK)

For

2010, 2011, 2012, 2013

Liquidity Measurement Ratios

Profitability Indicator Ratios

Financial Leverage Ratio

Page 51: Ratios Glaxo Smith Kline

3 Price/Book Value Ratio 7.32 9.20 7.32 9.20 8.26

4 Price/Earnings Ratio 39.75 14.04 13.47 12.74 20.00

Page 52: Ratios Glaxo Smith Kline

ABBOTReturn On Equity (ROE)

Net Income (NI)

Total Asset (TA)

Average Total Asset (Avg TA)

Shareholder Equity (ShEq)

Average Shareholder Equity (Avg ShEq)

Revenue (Rev)

Earnings before Taxes (EBT)

Earnings before Interest and Taxes (EBIT)

Formula:

DuPont is an “analysis” it’s a tool to compare a company to itself and to its competitors.

1. ROE

= (NI / Avg TA) x (Avg TA / Avg ShEq)

= ROA  x  Leverage

2. ROE

= (NI / Rev) x (Rev / Avg TA) x (Avg TA / Avg ShEq)

= Net Profit Margin  x  Asset Turnover  x  Leverage

3. ROE

= (NI / EBT) x (EBT / EBIT) x (EBIT / Rev) x (Rev / Avg TA) x (Avg TA / Avg ShEq)

= Tax Burden  x  Interest Burden  x  EBIT Margin  x  Asset Turnover  x  Leverage

Where:

ROE = Return on Equity

NI = Net Income

Avg TA = Average Total Assets

Avg ShEq = Average Shareholder Equity

Rev = Revenue

EBT = Earnings before Taxes

EBIT = Earnings before Interest and Taxes

ABBOT

Dupont Analysis

ABBOT

As of 31st December 2010, 2011, 2012

USD RS. in Rupees

Page 53: Ratios Glaxo Smith Kline

Return On Equity (ROE)

Tax Burden

Interest Burden

EBIT Margin

Asset Turnover

Laverage

ROE

Abbot has strong ROE over the 3-years.  The range is between 22% and 31%. 

This range is a bit large, but is on the high side and the low is far above the 09% requirement.

Page 54: Ratios Glaxo Smith Kline

Dec 31, 2010 Dec 31, 2011 Dec 31, 201221.69% 50.53% 11.42%

#REF! #REF! #REF!

14,891,799 15,437,585 16,243,325

4,020,700 6,597,875 8,367,595

10,799,814 11,108,572 11,471,591

2,515,112 4,549,361 5,946,788

18,916,191 21,750,147 23,149,964

1,931,724 2,236,888 2,312,096

#REF! #REF! #REF!

Dec 31, 2010 Dec 31, 2011 Dec 31, 2012

Dupont Analysis

ABBOT

As of 31st December 2010, 2011, 2012

USD RS. in Rupees

Page 55: Ratios Glaxo Smith Kline

#REF! #REF! #REF!

#REF! #REF! #REF!

#REF! #REF! #REF!

#REF! #REF! #REF!

4.70470 3.29654 2.76662

1.59862 1.45029 1.40708

Page 56: Ratios Glaxo Smith Kline

Description Dec 31, 2010 Dec 31, 2011 Dec 31, 2012

Cash Flow From Operating Activities

cash genrated from operations 3647883 1402378

financial charges pad -2369 -

staff retirement benefit paid -53016 -205481

taxes paid -1147359 -1061460

increase in long term loans to employees -12291 -8415

decrease in long term deposits 476 91

net cash generated from operating activities 2433324 127113

Cash Flow From Investing Activities

fixed capital expenditure -789884 -834597 -1497581

proceeds from sale of operating assets 34278 93840 152891

investimetns encashed - 175000 -

return on investiments PIBS 16275 7945 -

net cash used in investing activities -739331 -557812 -1344690

Cash Flow From Financing Activities

Dividend Paid -849019 -782165 -900008

Net(decrease)/Increase in cash and cash equivalents 844974 -1212864 -9888

cash and cash equivalents at beginning of the year 2693522 3538496 2325632

cash and cash equivalents at end of the year 3538496 2325632 2315744

Balance Sheet

Glaxo Smith Kline (GSK)

As of 31st December 2010, 2011, 2012

Rs. in (000)